S
Savara Inc
SVRACIK 0001160308NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-118.84M
Total Assets
$253.44M
Equity
$203.13M
Shares Out
204.93M
Op. Cash Flow
$-101.00M
Business
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program, MOLBREEVI (molgramostim inhalation solution), is an investigational inhaled biologic containing recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (PAP). The company does not manufacture; it outsources development and manufacturing to contract vendors and holds exclusive rights to the drug-device combination comprising MOLBREEVI and PARI's proprietary eFlow® Nebulizer System. Savara pursues regulatory approval in the U.S., EU, and UK, with a resubmitted BLA pending FDA Priority Review following an initial refusal to file in May 2025.
Summary from 10-K filed 2026-03-13
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 81 | 78 | 44 | 28 | 29 | |
| General and administrative | 42 | 25 | 16 | 11 | 12 | |
| Depreciation and amortization | 87,000 | 130,000 | 77,000 | 31,000 | 136,000 | |
| Total operating expenses | 124 | 103 | 60 | 39 | 41 | |
| Loss from operations | −124 | −103 | −60 | −39 | −41 | |
| Interest income, net | 4 | 6 | 4 | −88,000 | −2 | |
| Foreign currency exchange gain | 310,000 | 51,000 | 76,000 | −19,000 | −99,000 | |
| Tax credit income | 784,000 | 797,000 | 797,000 | 796,000 | 844,000 | |
| Loss on extinguishment of debt | −546,000 | — | — | — | — | |
| Total other income, net | 5 | 7 | 5 | 689,000 | −2 | |
| Net loss | −119 | −96 | −55 | −38 | −43 | |
| Basic (per share) | −0.53 | −0.48 | −0.33 | −0.25 | −0.32 | |
| Diluted (per share) | −0.53 | −0.48 | −0.33 | −0.25 | −0.32 | |
| Basic (shares) | 222 | 198 | 165 | 153 | 134 | |
| Diluted (shares) | 222 | 198 | 165 | 153 | 134 | |
| Gain (loss) on foreign currency translation | 665,000 | −523,000 | 133,000 | −648,000 | −887,000 | |
| Unrealized gain (loss) on short-term investments | −2,000 | 44,000 | 201,000 | 38,000 | −50,000 | |
| Total comprehensive loss | −118 | −96 | −54 | −39 | −44 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 33 | 15 | 27 | 52 | 34 | |
| Short-term investments | 203 | 181 | 136 | 74 | 127 | |
| Prepaid expenses and other current assets | 6 | 6 | 4 | 3 | 4 | |
| Total current assets | 242 | 202 | 166 | 129 | 165 | |
| Property and equipment, net | 100,000 | 165,000 | 270,000 | 51,000 | 73,000 | |
| In-process R&D | 12 | 10 | 11 | 11 | 11 | |
| Other non-current assets | 84,000 | 242,000 | 387,000 | 116,000 | 251,000 | |
| Total assets | 253 | 213 | 178 | 140 | 177 | |
| Accounts payable | 6 | 5 | 4 | 1 | 1 | |
| Accrued expenses and other current liabilities | 15 | 10 | 7 | 5 | 5 | |
| Total current liabilities | 20 | 15 | 11 | 6 | 15 | |
| Long-term debt | 30 | 27 | 26 | 26 | 17 | |
| Other long-term liabilities | 0 | 87,000 | 247,000 | 54,000 | 117,000 | |
| Total liabilities | 50 | 41 | 37 | 32 | 32 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2025 and 2024; 204,567,283 and 172,423,223 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 204,000 | 173,000 | 140,000 | 116,000 | 116,000 | |
| Additional paid-in capital | 811 | 661 | 534 | 447 | 445 | |
| Accumulated other comprehensive loss | −87,000 | −750,000 | −271,000 | −605,000 | 5,000 | |
| Accumulated deficit | −608 | −489 | −393 | −339 | −301 | |
| Total stockholders equity | 203 | 171 | 140 | 108 | 144 | |
| Total liabilities and stockholders' equity | 253 | 213 | 178 | 140 | 177 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −119 | −96 | −55 | −38 | −43 | |
| Reduction in the carrying value of right-of-use assets | 158,000 | 145,000 | 98,000 | 136,000 | 231,000 | |
| Amortization of debt issuance costs | 453,000 | 271,000 | 271,000 | 334,000 | 552,000 | |
| Accretion on discount to short-term investments | −3 | −5 | −5 | 75,000 | 2 | |
| Stock-based compensation | 14 | 10 | 4 | 2 | 3 | |
| Prepaid expenses and other current assets | 97,000 | −2 | −456,000 | 1 | −1 | |
| Non-current assets | 98,000 | 11,000 | −12,000 | −57,000 | — | |
| Accounts payable and accrued expenses and other current liabilities | 5 | 4 | 5 | −319,000 | −2 | |
| Net cash used in operating activities | −101 | −89 | −51 | −35 | −40 | |
| Purchase of property and equipment | −22,000 | −25,000 | −296,000 | −9,000 | −57,000 | |
| Purchase of available-for-sale securities, net | −205 | −205 | −194 | −89 | −161 | |
| Maturity of available-for-sale securities | 182 | 165 | 137 | 131 | 83 | |
| Sale of available-for-sale securities, net | 4 | — | — | 11 | 8 | |
| Net cash used in investing activities | −18 | −40 | −57 | 53 | −69 | |
| Repayment of long-term debt | −27 | — | — | −26 | — | |
| Proceeds from long-term debt, net | 30 | — | — | 26 | — | |
| Issuance of common stock issued in underwritten offering, net of offering costs | 140 | 94 | — | — | — | |
| Issuance of common stock upon exercise of prefunded warrants | 2,000 | 7,000 | — | — | — | |
| Issuance of common stock upon at the market offerings, net | — | 24 | 9 | — | — | |
| Proceeds from exercise of stock options | 347,000 | 347,000 | 283,000 | 2,000 | 16,000 | |
| Reimbursement of commissions from the prior issuance of common stock upon at the market sales, net | — | 46,000 | — | — | — | |
| Repurchase of shares for minimum tax withholdings | −5 | −995,000 | −1 | −3,000 | −78,000 | |
| Net cash provided by financing activities | 138 | 118 | 83 | 87,000 | 121 | |
| Effect of exchange rate changes on cash and cash equivalents | −277,000 | −5,000 | −118,000 | −90,000 | −137,000 | |
| Increase (decrease) in cash and cash equivalents | 18 | −11 | −26 | 18 | 11 | |
| Cash paid for interest | 3 | 2 | 2 | 2 | 2 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Savara Inc's CIK number?
Savara Inc's SEC CIK number is 0001160308 (1160308). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Savara Inc's SEC filings?
All of Savara Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.